{"id":13700,"date":"2005-09-19T00:00:00","date_gmt":"2005-09-19T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/uncategorized\/m004mtg183\/"},"modified":"2019-03-01T15:04:42","modified_gmt":"2019-03-01T15:04:42","slug":"m004mtg183","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m004mtg183\/","title":{"rendered":"6th Annual Phase IV Clinical Trials"},"content":{"rendered":"

Featured Conference<\/b> <\/p>\n

6th Annual Phase IV Clinical Trials<\/a><\/b>
September 19 – 20, 2005 * Philadelphia, PA <\/p>\n

Visit the conference website<\/a> for more information and to register.<\/b> <\/p>\n<\/p>\n

Phase IV studies have emerged as a powerful tool for companies to get their drugs to be used more broadly and for longer periods.\u00a0 The growth rate of Phase IV spending is continuing to increase.\u00a0 A Tufts Center for the Study of Drug Development analysis found that between 1998 and 2003, the U.S. FDA requested Post-Marketing commitments in 73% of the approvals for new drugs not previously approved in the U.S.\u00a0 Also, the FDA reported in March 2004 that there is 1,000 open commitment post-approval clinical and non-clinical toxicology studies. At this point less than 20% of post-approval studies are completed.\u00a0<\/p>\n

Attend CBI\u2019s annual conference and gain insight from the regulatory, clinical, marketing, adverse events and Post-Marketing perspectives.\u00a0 The program provides a unique forum in which you can network with industry executives and Phase IV teams who can share their valuable experiences with you.<\/p>\n

The 2005 program covers the latest issues on Phase IV studies including:<\/p>\n